Unknown

Dataset Information

0

ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance.

ABSTRACT: During the past decade, more than 10 targetable oncogenic driver genes have been validated in non-small cell lung cancer (NSCLC). Anaplastic lymphoma kinase (ALK) and ROS1 kinase are two new driver genes implicated in ALK- and ROS1-rearranged NSCLC. Inhibition of ALK and ROS1 by crizotinib has been reported to be highly effective and well tolerated in these patients. However, resistance to crizotinib emerges years after treatment, and increasing efforts have been made to overcome this issue. Here, we review the biology of ALK and ROS1 and their roles in cancer progression. We also summarize the ongoing and completed clinical trials validating ALK and ROS1 as targets for cancer treatment. In the last section of the review, we will discuss the molecular mechanisms of crizotinib resistance and focus approaches to overcome it. This review describes an exciting new area of research and may provide new insights for targeted cancer therapies.

SUBMITTER: Ye M 

PROVIDER: S-EPMC4914285 | biostudies-literature | 2016 Mar

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance.

Ye Mingxiang M   Zhang Xinxin X   Li Nan N   Zhang Yong Y   Jing Pengyu P   Chang Ning N   Wu Jianxiong J   Ren Xinling X   Zhang Jian J  

Oncotarget 20160301 11

During the past decade, more than 10 targetable oncogenic driver genes have been validated in non-small cell lung cancer (NSCLC). Anaplastic lymphoma kinase (ALK) and ROS1 kinase are two new driver genes implicated in ALK- and ROS1-rearranged NSCLC. Inhibition of ALK and ROS1 by crizotinib has been reported to be highly effective and well tolerated in these patients. However, resistance to crizotinib emerges years after treatment, and increasing efforts have been made to overcome this issue. Her  ...[more]

Similar Datasets

Unknown The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.
| S-EPMC4707106 | biostudies-literature
Unknown ALK-driven tumors and targeted therapy: focus on crizotinib.
| S-EPMC3977456 | biostudies-other
Unknown ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it.
| S-EPMC4367701 | biostudies-literature
Unknown PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.
| S-EPMC4371934 | biostudies-literature
Unknown Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.
| S-EPMC4286456 | biostudies-literature
Unknown Iruplinalkib (WX‑0593), a novel ALK/ROS1 inhibitor, overcomes crizotinib resistance in preclinical models for non-small cell lung cancer.
| S-EPMC10140010 | biostudies-literature
Unknown Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance.
| S-EPMC3947539 | biostudies-literature
Unknown Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.
| S-EPMC3088626 | biostudies-literature
Unknown Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial.
| S-EPMC8888601 | biostudies-literature
Unknown Acquired resistance to crizotinib from a mutation in CD74-ROS1.
| S-EPMC3878821 | biostudies-literature